Medicenna Therapeutics Corp.
MDNAF evidence brief
What we can confirm
- Market Cap:
- $27.7M
What it means
What to watch
Prepared research question
What matters most for MDNAF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MDNAF
Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage immunotherapy company developing Superkines for cancer, autoimmune, and inflammatory diseases, with lead programs MDNA11 (IL-2 Superkine) and bizaxofusp (formerly MDNA55) for glioblastoma.
Key risk: No approved products
Market Cap
$27.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 1 clinical trial for Medicenna Therapeutics Corp..
Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage immunotherapy company developing Superkines for cancer, autoimmune, and inflammatory diseases, with lead programs MDNA11 (IL-2 Superkine) and bizaxofusp (formerly MDNA55) for glioblastoma.
- Medicenna is a clinical-stage immunotherapy company developing Superkines for cancer and autoimmune disease [news · published 2026-09-24].
- Lead program MDNA11 (IL-2 Superkine) is in a Phase 1/2 ABILITY-1 study, with enrollment on track for completion in Q3 2026 [news · published 2026-08-14].
- Bizaxofusp (formerly MDNA55) is being evaluated for unresectable, IDH-wildtype recurrent glioblastoma, with an oral presentation at the 2026 Society for Neuro-Oncology Annual Meeting [news · published 2026-09-24].
- The company raised CDN$4.44 million through a public offering of units in May 2026 [news · published 2026-05-28].
- Medicenna's global patent portfolio exceeds 100 active granted patents and applications, including new U.S. patents for IL-2, IL-4, and IL-13 Superkine platforms [news · published 2026-06-11].
What works
- Medicenna has a strong and growing intellectual property portfolio, with over 100 active granted patents and applications globally, providing broad protection for its Superkine platforms [news · published 2026-06-11].
- The company has multiple clinical catalysts in 2026, including oral presentations of updated MDNA11 and bizaxofusp data at upcoming medical conferences, indicating active pipeline progress [news · published 2026-08-14].
- Medicenna successfully closed a public offering raising CDN$4.44 million in May 2026, providing near-term funding to support lead programs [news · published 2026-05-28].
What to weigh
- Medicenna is a clinical-stage company with no approved products, meaning it is entirely dependent on successful clinical development and regulatory approvals for future revenue [news · published 2026-09-24].
- The company's lead programs target highly competitive and technically challenging areas (e.g., glioblastoma, advanced solid tumors), where many therapies have failed historically [news · published 2026-08-14].
- The public offering of units at CDN$0.50 per unit suggests the company is raising capital at a relatively low price point, which may indicate financial pressure or dilution for existing shareholders [news · published 2026-05-28].
From the filings
Quoted directly from source documents.
Medicenna is a clinical-stage immunotherapy company developing Superkines.
“Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease”
News · September 24, 2026
Bizaxofusp results in recurrent glioblastoma will be presented at the 2026 Society for Neuro-Oncology Annual Meeting.
“an abstract evaluating survival outcomes with bizaxofusp (formerly MDNA55) in unresectable, IDH-wildtype recurrent glioblastoma (rGBM) has been selected for an oral presentation at the 31st Annual Meeting of the Society for Neuro-”
News · September 24, 2026
Enrollment in the Phase 1/2 ABILITY-1 study is on track for completion in Q3 2026.
“Enrolment in the Phase 1/2 ABILITY-1 study remains on track for completion in Q3 2026”
News · August 14, 2026
Medicenna closed a public offering raising CDN$4.44 million.
“Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs”
News · May 28, 2026
Catalyst timeline
- 2021-08-27 · Phase 1/2 ABILITY-1 study start (MDNA11) — A Phase 1/2 open-label, dose escalation and expansion study of MDNA11, an IL-2 Superkine, administered alone or in combination with an immune checkpoint inhibitor in patients with advanced solid tumors.
Risks & what to watch (3)›
Key risks
- No approved products — Medicenna has no marketed products; all revenue depends on future clinical and regulatory success [news · published 2026-09-24].
- Competitive oncology landscape — Lead programs target glioblastoma and advanced solid tumors, areas with high historical failure rates and intense competition [news · published 2026-08-14].
- Dilutive financing — The May 2026 public offering at CDN$0.50 per unit may dilute existing shareholders and indicates potential cash constraints [news · published 2026-05-28].
What to watch
- Oral presentation of bizaxofusp survival data at the 2026 Society for Neuro-Oncology Annual Meeting [news · published 2026-09-24].
- Updated MDNA11 clinical results from ABILITY-1 at an upcoming medical conference [news · published 2026-08-14].
- Completion of enrollment in the Phase 1/2 ABILITY-1 study, expected in Q3 2026 [news · published 2026-08-14].
- Potential regulatory discussions regarding an expedited path for bizaxofusp [news · published 2026-08-14].
Sources: Catalysts · Competitor trials · News · Generated October 13, 2026 · How we verify sources →
Run Medicenna Therapeutics Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Medicenna Therapeutics Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2024Institutional holders
1
Total value held
$200K
| Holder | Shares | Value |
|---|---|---|
| org partners llc | 175,000 | $200K |
Short Interest
as of Apr 30, 2026- % of float
- 0.7%
- Days to cover
- 0.8
- Shares short
- 109,389
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MDNAF short interestGovernance
Frequently asked questions
What is the AI investment thesis for Medicenna Therapeutics Corp.?
Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage immunotherapy company developing Superkines for cancer, autoimmune, and inflammatory diseases, with lead programs MDNA11 (IL-2 Superkine) and bizaxofusp (formerly MDNA55) for glioblastoma.
Who is the CEO of Medicenna Therapeutics Corp.?
Dr. Fahar Merchant Ph.D. is the chief executive officer of Medicenna Therapeutics Corp. (MDNAF).
Where is Medicenna Therapeutics Corp. headquartered?
Medicenna Therapeutics Corp. (MDNAF) is headquartered in Toronto, ON, Canada.
What therapeutic areas does Medicenna Therapeutics Corp. focus on?
Medicenna Therapeutics Corp. develops therapies across Oncology, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.